Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 46, 2015, Pages 14325-14330

  Tolaney, Sara M ^a   Boucher, Yves ^b   Duda, Dan G ^b   Martin, John D ^b,e   Seano, Giorgio ^b   Ancukiewicz, Marek ^b,f   Barry, William T ^a   Goel, Shom ^a,b   Lahdenrata, Johanna ^b,g   Isakoff, Steven J ^b   Yeh, Eren D ^d   Jain, Saloni R ^b,c,h   Golshan, Mehra ^d   Brock, Jane ^d   Snuderl, Matija ^b,i   Winer, Eric P ^a   Krop, Ian E ^a   Jain, Rakesh K ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f PAREXEL INTERNATIONAL   (United States)

^g MERRIMACK PHARMACEUTICALS   (United States)

^h Boston University   (United States)

ⁱ NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiangiogenic therapy; Cellular proliferation; Circulating and tissue biomarkers; PAM50 gene signature

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CYCLOPHOSPHAMIDE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PACLITAXEL; PLACENTAL GROWTH FACTOR; SOLUBLE TIE2 RECEPTOR; SOLUBLE VASCULOTROPIN RECEPTOR 1; SOLUBLE VASCULOTROPIN RECEPTOR 2; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ANTIANGIOGENIC THERAPY; ARTICLE; BASAL LIKE BREAST CANCER; BLOOD VESSEL PARAMETERS; BREAST ADENOCARCINOMA; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CAPILLARY DENSITY; CORRELATIONAL STUDY; DOSE DENSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; EXPLORATORY RESEARCH; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MONOTHERAPY; ONCOLOGICAL PARAMETERS; PERICYTE COVERED VESSEL PERIMETER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TISSUE PRESSURE; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; ADULT; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; FEMALE; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; VASCULARIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84947609778     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1518808112     Document Type: Article

References (58)

1. Jain RK (2014) Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26(5):605-622.
2. Sledge GW (2015) Anti-vascular endothelial growth factor therapy in breast cancer: Game over? J Clin Oncol 33(2):133-135.
3. Fisher B, et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8):2672-2685.
4. Kuerer HM, et al. (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460-469.
5. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 97(3):188-194.
6. Von Minckwitz G, et al.; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Study Groups (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366(4):299-309.
7. Sikov WM, et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33(1):13-21.
8. Earl HM, et al.; ARTemis Investigators (2015) Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): An open-label, randomised, phase 3 trial. Lancet Oncol 16(6):656-666.
9. Bear HD, et al. (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366(4):310-320.
10. Cameron D, et al. (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial. Lancet Oncol 14(10):933-942.
11. Batchelor TT, et al. (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110(47):19059-19064.
12. Heist RS, et al. (2015) Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci USA 112(5):1547-1552.
13. Garcia-Foncillas J, et al. (2012) Dynamic contrast-enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer. J Clin Oncol 30(Suppl):10512 (abstr).
14. Sorensen AG, et al. (2009) A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69(13):5296-5300.
15. Sorensen AG, et al. (2012) Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72(2):402-407.
16. Lambrechts D, Lenz H-J, De Haas S, Carmeliet P, Scherer SJ (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31(9):1219-1230.
17. Greenberg J I, et al. (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456(7223):809-813.
18. Winkler F, et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553-563.
19. Jain RK, Tong RT, Munn LL (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model. Cancer Res 67(6):2729-2735.
20. Willett CG, et al. (2005) Surrogate markers for antiangiogenic therapy and doselimiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23(31):8136-8139.
21. Zardavas D, Irrthum A, Swanton C, Piccart M (2015) Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol 12(7):381-394.
22. Willett CG, et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145-147.
23. Yang SX, et al. (2008) Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 14(18):5893-5899.
24. Gasparini G, et al. (2012) A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 15(1):141-150.
25. Foernzler D, et al. (2010) Tumor tissue based biomarker analysis in NO16966: A randomized phase III study of first-line bevacizumab in combination with oxaliplatinbased chemotherapy in patients with mCRC. ASCO Gastrointestinal Cancers Symposium (abstr 374). Available at meetinglibrary. asco.org/content/2207-72.
26. Vasudev NS, et al. (2013) Changes in tumour vessel density upon treatment with antiangiogenic agents: Relationship with response and resistance to therapy. Br J Cancer 109(5):1230-1242.
27. Verstraete M, et al. (2015) Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial. Br J Cancer 112(8):1314-1325.
28. Jeong H-S, et al. (2015) Investigation of the lack of angiogenesis in the formation of lymph node metastases. J Natl Cancer Inst 107(9): djv155.
29. Rønnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction. Physiol Rev 76(1):69-125.
30. De Kruijf EM, et al. (2011) Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 125(3):687-696.
31. Stylianopoulos T, et al. (2012) Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA 109(38):15101-15108.
32. Chauhan VP, et al. (2013) Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 4:2516.
33. Chauhan VP, et al. (2014) Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 26(1):14-15.
34. Hutchison GJ, et al. (2004) Hypoxia-inducible factor 1a expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 10(24):8405-8412.
35. Lehmann S, et al. (2009) Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci USA 106(33):14004-14009.
36. Mayer A, et al. (2004) Lack of correlation between expression of HIF-1a protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res 64(16):5876-5881.
37. Mazzone M, et al. (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136(5):839-851.
38. Huang Y, et al. (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109(43):17561-17566.
39. Tong RT, et al. (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64(11):3731-3736.
40. Duda DG, et al. (2010) Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 15(6):577-583.
41. Lambrechts D, et al. (2012) VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 13(7):724-733.
42. Meyerhardt JA, et al. (2012) Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One 7(6):e38231.
43. Zhu AX, et al. (2013) Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study. Clin Cancer Res 19(6):1557-1566.
44. Raut CP, et al. (2012) Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One 7(2):e26331.
45. Andre F, Deluche E, Bonnefoi H (2015) Bevacizumab: The phoenix of breast oncology? Lancet Oncol 16(6):600-601.
46. Goel S, et al. (2013) Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst 105(16):1188-1201.
47. Patenaude A, et al. (2015) A novel population of local pericyte precursor cells in tumor stroma that require Notch signaling for differentiation. Microvasc Res 101:38-47.
48. Abraham S, et al. (2015) A Rac/Cdc42 exchange factor complex promotes formation of lateral filopodia and blood vessel lumen morphogenesis. Nat Commun 6:7286.
49. Rivera LB, Bergers G (2015) CANCER. Tumor angiogenesis, from foe to friend. Science 349(6249):694-695.
50. Symmans WF, et al. (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414-4422.
51. Ogston KN, et al. (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast 12(5):320-327.
52. Network TCGA; Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
53. Parker JS, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160-1167.
54. Less JR, et al. (1992) Interstitial hypertension in human breast and colorectal tumors. Cancer Res 52(22):6371-6374.
55. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK (1991) Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51(24):6691-6694.
56. Batchelor TT, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1):83-95.
57. Chen S, et al. (2015) Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptorpositive but not hormone receptor-negative locally advanced breast cancer. Ann Surg Oncol 22(1):32-39.
58. Zhu Q, et al. (2014) Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria. Breast Cancer Res 16(5):456.